Suchergebnisse - "Mamdani, Hirva"

PubPharm (60)

1

Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non-Small-Cell Lung Cancer

enthalten in: JCO precision oncology | 2024

von Naqash, A. | Floudas, C. | Aber, E. | +21

2

Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer

enthalten in: Clinical pharmacokinetics | 2024

von Chen, J. | Bearz, A. | Kim, D. | +14

3

Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Burns, L. | Hsu, C. | Whisenant, J. | +26

4

Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer

enthalten in: Clinical pharmacokinetics | 2023

von Chen, J. | Bearz, A. | Kim, D. | +14

5

Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer : A Randomized Clinical Trial

enthalten in: JAMA oncology | 2023

von Takahashi, N. | Hao, Z. | Villaruz, L. | +35

6

Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma : HCRN-LUN15-299

enthalten in: JTO clinical and research reports | 2023

von Dudek, A. | Xi, M. | Scilla, K. | +5

7

Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations : ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Cornelissen, R. | Prelaj, A. | Sun, S. | +14

CommentIn: J Thorac Oncol. 2023 Aug;18(8):964-966. - PMID 37479324

8

The Role of Surgery in Stage I Small Cell Lung Cancer : A National VA Database Analysis

enthalten in: Clinical lung cancer | 2023

von Azar, I. | Austin, A. | Saha, B. | +12

9

A Brief Report of a Phase II trial Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer

enthalten in: Clinical lung cancer | 2023

von Wei, C. | Mamdani, H. | Gentzler, R. | +4

10

Senescence-associated secretory proteins induced in lung adenocarcinoma by extended treatment with dexamethasone enhance migration and activation of lymphocytes

enthalten in: Cancer immunology, immunotherapy : CII | 2023

von Parajuli, P. | Rosati, R. | Mamdani, H. | +7

1
2
3
4
5
6
Nächster »
[6]